Earnings ·
Reports Q3 net loss of $61.9M on $13.2M revenue; cash runway extends to 3Q 2028
WVEWave Life Sciences, Inc.
Wave Life Sciences reported a third-quarter net loss of $61.9 million, or $0.30 per share, compared to a $53.9 million loss in the prior-year period. Revenue rose to $13.2 million from $7.6 million, driven by collaboration income, while R&D and G&A expenses increased to $53.8 million and $25.4 million, respectively. The company holds $431.0 million in cash and marketable securities as of September 30, 2026, excluding a pending $12 million milestone from GSK expected in the fourth quarter. This balance supports operations into the third quarter of 2028. Pipeline updates include planning for a registrational trial of WVE-006 for AATD following FDA alignment and ongoing Phase 2a dosing for obesity candidate WVE-007. Wave Life Sciences is a clinical-stage biotechnology company focused on developing RNA medicines.